title: [Extracorporeal treatment with L-asparaginase (author's transl)].
abstract: L-asparaginase therapy is often limited by allergy or toxicity and probably in some cases by antibody mediated inactivation of the enzyme. These problems can be avoided by extracorporeal application of l-asparaginase. As the enzyme is a stable tetramer with high molecular weight it cannot pass through the dialysis membrane in contrast to the amino acid l-asparagin which is destroyed. The resulting l-asparagin depletion of the plasma is  sufficient for therapeutic success. Effective extracorporeal l-asparaginase therapy is demonstrated in two patients with ALL who were resistant to other chemotherapy and could not be treated intravenously because of allergy and toxicity.
mesh_terms: D000328:Adult; D000707:Anaphylaxis; D000906:Antibodies; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D005112:Extracorporeal Circulation; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D008970:Molecular Weight
chemical_list: D000906:Antibodies; D001215:Asparaginase
references.citation: Med Klin. 1969 Jan 3;64(1):9-12
references.pmid: 4883526
references.citation: Eur J Cancer. 1973 Jan;9(1):55-7
references.pmid: 4703689
references.citation: Lancet. 1975 Jun 7;1(7919):1293-4
references.pmid: 48918
references.citation: Cancer. 1971 Feb;27(2):247-56
references.pmid: 5100389
references.citation: J Pediatr. 1972 Jul;81(1):109-11
references.pmid: 5034858
references.citation: Med Klin. 1972 Aug 4;67(31):1011-7
references.pmid: 4506638
references.citation: Cancer Res. 1977 Feb;37(2):535-40
references.pmid: 264412
references.citation: Recent Results Cancer Res. 1970;33:244-56
references.pmid: 5292719
references.citation: J Exp Med. 1963 Jul;118:99-120
references.pmid: 14015821
references.citation: Cancer Res. 1973 Aug;33(8):1966-9
references.pmid: 4578567
references.citation: J Surg Oncol. 1974;6(1):39-48
references.pmid: 4206597
references.citation: Tidsskr Nor Laegeforen. 1972 Mar 10;92(7):502-5
references.pmid: 5035499
references.citation: Cancer. 1976 Jan;37(1):220-8
references.pmid: 1061636
references.citation: Cancer Res. 1973 Jan;33(1):1-4
references.pmid: 4565907
references.citation: Cancer. 1975 Jan;35(1):25-35
references.pmid: 1053694
references.citation: J Lab Clin Med. 1969 Sep;74(3):521-6
references.pmid: 4308912
references.citation: Lancet. 1967 Aug 19;2(7512):380-2
references.pmid: 4166329
references.citation: Br Med J. 1974 Jul 13;3(5923):81-3
references.pmid: 4604804
references.citation: Arzneimittelforschung. 1968 Nov;18(11):1380-6
references.pmid: 4885156
references.citation: Klin Wochenschr. 1969 Jan 15;47(2):65-71
references.pmid: 4904782
references.citation: Cancer. 1974 Mar;33(3):626-30
references.pmid: 4521886
references.citation: Blut. 1974 Jan;28(1):43-50
references.pmid: 4521087
references.citation: Cancer. 1972 May;29(5):1347-51
references.pmid: 4553763
references.citation: Cancer. 1972 Aug;30(2):339-47
references.pmid: 4626307
vernacular_title: Extrakorporale Asparaginasetherapie bei Allergie und toxischen Nebenwirkungen.